title: DPP-IV inhibitory potential of naringin: an in silico, in vitro and in vivo study.
abstract: The incretin based therapies are an emerging class of antidiabetic drugs, with two categories: one is glucagone like peptide-1 (GLP-1) agonists and the other one is dipeptidyl peptidase (CD26; DPP-IV) inhibitors. However, in the DPP-IV inhibitors category only few compounds are commercially available and also have some undesirable effects. Therefore, in the present work we tried to explore a naturally occurring compound naringin for its potential DPP-IV inhibition and antidiabetic potential. It is noteworthy that this compound is abundantly present in orange peel and thus may provide cost effective treatment for diabetes, especially type 2 diabetes mellitus. In the present study, we have conducted virtual docking study and observed tight binding of naringin, as shown by higher negative values of H bond lengths, while in vitro DPP-IV inhibition assay has also shown better inhibition by naringin. In vivo study, in response to 10 days administration of 40 mg/kg of naringin twice daily to Wistar albino rats, inhibited the serum levels of DPP-IV activity, random glucose concentration with concomitant increase in insulin levels. All the comparisons were made with the standard commercially available drug sitagliptin.
authors.affiliation: School of Biotechnology, Devi Ahilya University, Takshashila Campus, Khandwa Road, Indore 452001, MP, India. hamendrasingh999@gmail.com
authors.forename: Hamendra Singh
authors.initials: HS
authors.lastname: Parmar
authors.forename: Palak
authors.initials: P
authors.lastname: Jain
authors.forename: Digvijay Singh
authors.initials: DS
authors.lastname: Chauhan
authors.forename: Mahesh Kumar
authors.initials: MK
authors.lastname: Bhinchar
authors.forename: Vibhuti
authors.initials: V
authors.lastname: Munjal
authors.forename: Mohammed
authors.initials: M
authors.lastname: Yusuf
authors.forename: Krati
authors.initials: K
authors.lastname: Choube
authors.forename: Arpita
authors.initials: A
authors.lastname: Tawani
authors.forename: Vinita
authors.initials: V
authors.lastname: Tiwari
authors.forename: E
authors.initials: E
authors.lastname: Manivannan
authors.forename: Anil
authors.initials: A
authors.lastname: Kumar
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003198:Computer Simulation; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000201:enzymology; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000201:enzymology; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004334:Drug Administration Schedule; D005260:Female; D044950:Flavanones / Q000008:administration & dosage / Q000494:pharmacology*; D052216:Glucagon-Like Peptide 1 / Q000819:agonists; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D066298:In Vitro Techniques; D007328:Insulin / Q000378:metabolism; D015227:Lipid Peroxidation; D008297:Male; D010179:Pancreas / Q000187:drug effects* / Q000201:enzymology; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D044950:Flavanones; D007004:Hypoglycemic Agents; D007328:Insulin; D052216:Glucagon-Like Peptide 1; C005274:naringin